Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of “Hold” by Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has earned an average rating of “Hold” from the twenty analysts that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $81.8421.

Several equities research analysts have weighed in on the company. Piper Sandler cut Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. Weiss Ratings cut Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Mizuho dropped their price objective on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Jefferies Financial Group dropped their price objective on Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating for the company in a report on Thursday, February 12th. Finally, Stifel Nicolaus dropped their price objective on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, May 5th.

Inspire Medical Systems Price Performance

Shares of INSP stock opened at $43.16 on Friday. The stock has a market capitalization of $1.24 billion, a PE ratio of 9.61, a P/E/G ratio of 4.36 and a beta of 0.83. Inspire Medical Systems has a 1-year low of $39.61 and a 1-year high of $147.03. The business has a 50-day moving average of $50.41 and a 200 day moving average of $75.17.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. During the same period in the prior year, the business posted $0.10 EPS. Inspire Medical Systems’s quarterly revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Analysts anticipate that Inspire Medical Systems will post 0.91 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INSP. CWM LLC grew its holdings in Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares in the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems during the fourth quarter valued at $40,000. Finally, Smartleaf Asset Management LLC raised its stake in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.